General Info

Be Biotechnologies is a biopharmaceutical, founded on cannabinoid and plant-based research, development, and Evidence-based drug development (EBD), aimed at transforming knowledge from biopharmaceutical sciences into new pharmaceutical drugs for animals and humans. For Evidence-based drug development (EBD), our R&D Team is working with several internal researchers and in collaboration around the world, using a decentralized development, using a Cloud Lab to development the Drug Candidates, increase experimental output, repeating the past work or deepen the analysis at the push of a button. A Board of Curators and Biomedical experts evaluates all the work, analysis of the new Drug Candidate using the advantage of Artificial Intelligence. Focus on intellectual contribution instead of manual labor. These Plant-Based Drug Candidates provide solutions to unmet medical needs in dermatology, anti-oxidant boosters for our astronauts, chronic pain, and various neurological diseases, providing patients access to more affordable and modern phyto-pharmaceutical treatments after regulatory clearance in each territory. Be Biotechnologies' commercial platform has resulted in over 20 different formulations for the development of commercial products, including cosmetics, wellness, and pharmaceuticals, besides the global distribution of APIs/RAW materials. Be Biotechnologies want to become the hub for microgravity plant science in space, understanding the three-dimensional structure of proteins is critical to life science and biopharmaceutical researchers. This information can be used for understanding disease mechanisms, identifying drug targets, and optimizing pharmaceutical drug design. In Partnership with NASA and ESA Implementation Partners, Be Biotechnologies wants to create the opportunity to deepen our drug development knowledge. Be Biotechnologies powered by AI. #bionyc #biomadrid #wearebiotech #bebiotech Instagram @bebiotechnologies